Life science-companies in Western Sweden take off – the “VGR-effect” is important

20 June, 2017

Opatus and Emeriti Pharma are among the West Swedish companies that receive funding in the joint project “Project for better health”. In total, SEK 11.7 million went to West Sweden projects. Co-financing from the Västra Götaland region is a welcome and a valuable “bonus”.

“To get a larger share of a project funded, obviously makes a big difference. I am very happy and grateful for this opportunity, which has already led to new possibilites, “says Petter Knagenhjelm, CEO, Opatus.

Opatus will conduct a clinical study on an objective measurement of activity, impulsivity and attention in ADHD. Emeriti Pharma develops treatment of psoriasis. The companies are coached by Sahlgrenska Science Park, which assisted companies throughout Western Sweden with counseling and pitch training, according to the Swelife hands-on model.

Interest has been extraordinary after VGR opened up for co-financing for West Sweden projects funded by Vinnova, which can be expected to contribute to growth in the region.

“It is gratifying that so many West Swedish life science companies now have the opportunity to further develop their innovations and extra fun that it is done in conjunction with our own healthcare. We strongly believe in such funding solutions when the region and state work together, “says Hanna Blomdahl, Group Staff, Regional Development.

The call promotes projects with a high potential for innovation in order to increase the usefulness of research and knowledge, which leads to improved health, increased growth and international competitiveness. It is in collaboration between Swelife and Medtech4Health  two nationally-funded strategic innovation programs in life science.